oxaliplatin / Generic mfg. - LARVOL DELTA

Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. (PubMed, N Engl J Med) - "A ctDNA-guided approach to the treatment of stage II colon cancer reduced adjuvant chemotherapy use without compromising recurrence-free survival. (Supported by the Australian National Health and Medical Research Council and others; DYNAMIC Australian New Zealand Clinical Trials Registry number, ACTRN12615000381583.)."

Circulating tumor DNA • Journal • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Phase II study of TAS-OX (TAS-102 and oxaliplatin) plus bevacizumab for late-line colorectal cancer. (ASCO-GI 2023) - P2 | " Eligibility included measurable CRC previously treated with all approved drugs per TAS package insert (irinotecan, oxaliplatin, 5FU, anti-VEGF, anti-EGF) as appropriate, PS = 0-1, labs within usual range, neuropathy < grade 2, ability to take oral meds, appropriate contraception...For the first 40 pts, 385 cycles were given (mean = 7 cycles, median 8) with 18 pts (45%) requiring dose reductions (1 dose reduction = 9 pts, 2 = 6, 3 = 3), and 9 receiving (peg)/filgrastim... In patients with late-line CRC and candidates for TAS (trifluridine/tipiracil), treatment with TAS plus OX is both well tolerated and active. RR is higher than single agent and 78% (95% CI, 60-91%) of patients had stable disease or response, with 60% receiving 8 or more cycles. Randomized trials comparing to single agent TAS are warranted in this setting."

P2 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Phase I dose-escalation study of trifluridine/tipiracil plus XB2001 and bevacizumab in chemorefractory advanced colorectal cancer: The TASKIN study (ESMO-GI 2024) - P1/2 | "This supports testing the combination of TAS-102 plus XB2001 (an IL-1α monoclonal antibody). In the phase 1/2 TASKIN study (NCT05201352), patients (pts) with chemorefractory metastatic CC after failure of oxaliplatin, irinotecan, and fluoropyrimidine were enrolled and received XB2001 from 250 mg to 1000 mg every 2 weeks plus FTD-TPI 35 mg/m2. FTD-TPI plus XB2001 and bevacizumab demonstrated acceptable safety with promising efficacy in chemorefractory metastatic CC. The study continues as a randomized phase 2 study comparing FTD-TPI and bevacizumab with or without XB2001."

IO biomarker • Metastases • P1 data • Anemia • Colorectal Cancer • Gastrointestinal Cancer • Hematological Disorders • Neutropenia • Oncology • Solid Tumor • Thrombocytopenia • CD8 • CTAG1B • IL6 • PD-L1

Trifluridine/tipiracil plus capecitabine and bevacizumab as upfront treatment for metastatic colorectal cancer: Results of the phase I TriComB study (ESMO-GI 2024) - P1/2 | "Here, we present safety and preliminary activity results of the phase 1 TriComB study, an open-label, multicenter, phase 1/2 trial, evaluating FTD/TPI in combination with cap and bev in mCRC pts. Patients with previously untreated mCRC, ineligible for oxaliplatin- and/or irinotecan- based regimens, were enrolled. The sequential combination of cap and FTD/TPI with bev is feasible. The phase 2 of the study is ongoing to evaluate antitumor activity of this regimen in the same patients' population."

Metastases • P1 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. (PubMed, Lancet Oncol) - P2 | "In patients with chemorefractory metastatic colorectal cancer, TAS-102 plus bevacizumab, as compared with TAS-102 monotherapy, was associated with a significant and clinically relevant improvement in progression-free survival with tolerable toxicity. The combination of TAS-102 plus bevacizumab could be a new treatment option for patients with refractory metastatic colorectal cancer and could be a practice-changing development."

Clinical • Journal • P2 data • Colorectal Cancer • Gastrointestinal Cancer • Hematological Disorders • Neutropenia • Oncology

Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study. (ASCO-GI 2023) - P3 | " The global phase 3 SUNLIGHT study enrolled pts aged ≥18 years with histologically confirmed mCRC, ECOG PS 0/1, and treated with 1-2 prior chemotherapy regimens in an advanced setting, including fluoropyrimidines, irinotecan, oxaliplatin, an anti-VEGF monoclonal antibody (if medically considered) and/or anti-EGFR monoclonal antibody for RAS wild-type tumors. FTD/TPI + Bev provided a statistically significant and a clinically meaningful 3.3-month improvement in OS, extending mOS up to 10.8 months, with a 39% reduction in the HR of death in pts with refractory mCRC and with a predictable and acceptable safety profile. Clinical trial information: NCT04737187."

Clinical • Metastases • P3 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

PRODIGE 68 - UCGI 38 - SOREGATT: A randomized phase II study comparing the sequences of regorafenib (reg) and trifluridine/tipiracil (t/t) after failure of standard therapies in patients (pts) with metastatic colorectal cancer (mCRC) (ESMO-GI 2024) - P2 | "We have designed this trial to evaluate if trt sequence has an impact on the number of pts who can received both trt and on survival. Pts with mCRC, ≥18 yo, ECOG PS 0-1, after failure of fluoropyrimidine-based chemotherapy combined with oxaliplatin and/or irinotecan plus EGFR (if RAS wild-type) and/or VEGF inhibitors were assigned in a 1:1 ratio in arm A (reg then t/t) or arm B (t/t then reg). SOREGATT trial results show that the trt feasibility, i.e. rate of pts able to receive at least 2 cycles of both trt, is better with the sequence t/t then reg. Secondary endpoints will allow to confirm if there is an impact on survival outcomes."

Clinical • Metastases • P2 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • EGFR

Randomized phase III trial of ramucirumab in combination with TAS102 (Trifluridin/Tipiracil) vs. TAS102 monotherapy in heavily pretreated metastatic colorectal cancer: The RAMTAS/IKF643 trial of the German AIO (AIO-KRK-0316) (ESMO 2024) - P3 | "Against this background, we conducted a randomized phase III trial to compare the efficacy and safety of FTD/TPI with or without ramucirumab (ram) in pts with heavily pretreated mCRC. Pts with mCRC previously treated with oxaliplatin, irinotecan, fluoropyrimidin, anti-EGFR antibodies (when indicated) and anti-angiogenics were randomized 1:1 to FTD/TPI (35 mg/m2 d1-5 and 8-12, q4w) with (arm A) or without (arm B) ram (8 mg/kg d1+15, q4w). The RAMTAS trial did not meet its primary endpoint of OS in the ITT population. However, adding ram to FTD/TPI selectively improved survival in heavily pretreated female pts and pts with left-sided mCRC. These findings support the personalization of treatment decisions in pts with mCRC failing multiple lines of standard therapy."

Clinical • Combination therapy • Late-breaking abstract • Metastases • Monotherapy • P3 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology

Lonsurf (Trifluridine/Tipiracil) Plus Chemotherapy in Metastatic Colorectal Cancer Prospective Study in Taiwan (clinicaltrials.gov) - P=N/A | N=97 | Completed | Sponsor: Chang Gung Memorial Hospital | Recruiting ➔ Completed

Trial completion • Colorectal Cancer • Oncology • Solid Tumor

Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial. (PubMed, Lancet Oncol) - P3 | "Along with improved clinical outcomes, these analyses suggest that sotorasib plus panitumumab could represent a valuable new treatment in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer."

HEOR • Journal • P3 data • Colorectal Cancer • Fatigue • Oncology • Pain • Solid Tumor • KRAS

An augmented intelligence mobile phone chatbot for medication adherence and toxicity management among patients with gastrointestinal cancers on capecitabine. (ASCO-QC 2022) - P=N/A | "Chemotherapy regimens included cape with oxaliplatin (50%), concurrent RT (30%), temozolomide (5%), and monotherapy (15%). Although Penny has not yet met its feasibility endpoint, the lessons learned from this first cohort have informed further refinements to the platform. Ongoing efforts aim to integrate Penny with the electronic health record and further train the chatbot’s NLP functionality to minimize medication- and symptom-related safety events, respectively. Clinical trial information: NCT05113264."

Adverse events • Clinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Alkylating agent-based vs oxaliplatin-based chemotherapy in neuroendocrine tumours according to the O6-methylguanine-DNA methyltransferase (MGMT) status: A randomized phase II study (MGMT-NET) on behalf of the French Group of Endocrine Tumors (GTE) and ENDOCAN-RENATEN network (ESMO 2023) - P=N/A | "Background Alkylating agents (ALKY, temozolomide, darcabazine and streptozotocin), and oxaliplatin (Ox) are the main chemotherapies used for advanced neuroendocrine tumours (NETs). Results will be also given by technique of MGMT evaluation during the meeting. Table: LBA54 Proficient MGMT Deficient MGMT Oxaliplatin-based ALK-based ALK-based Oxaliplatin-based Number of patients 23 33 27 19 Pancreas 8 12 18 14 Thoracic/unknown 11/4 16/5 7/2 4/1 ORR at 3 months (central review), n (%) 6 (26) 4 (12) 8 (31) 6 (32) Best ORR, n (%) 9 (39) 6 (18) 15 (56) 4 (21) Median PFS in months (95%CI) 12.2 (11.7-12.7) 11.3 (9.4-13.2) 14.6 (7.1-22.1) 12.9 (11.8-14.0) Median OS in months (95%CI) 34.3 (21.9-46.7) 50.2 (not defined) Not reached 48.8 (21.0-76.6) Conclusions ALKY provides a higher response rate for dMGMT-NET while Ox chemotherapy may be a better option in pMGMT-NET."

Clinical • Late-breaking abstract • P2 data • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor • ALK • MGMT

PSMD14 as a translational target in cancer and beyond: from deubiquitination mechanisms to drug resistance and precision therapy. (PubMed, Cancer Drug Resist) - "This review synthesizes current evidence demonstrating that PSMD14 drives therapeutic resistance across multiple malignancies, including resistance to cisplatin, oxaliplatin, temozolomide, anlotinib, tamoxifen, and bortezomib by deubiquitinating and stabilizing key effectors such as E2F1, ALK2, IMPDH2, estrogen receptor α, and proteasomal components. We critically evaluate the therapeutic landscape of PSMD14 inhibitors, from natural products (thiolutin) and synthetic agents (Capzimin, O-phenanthroline) to next-generation dual-target inhibitors, and discuss the clinical barriers to translation, including off-target toxicity, patient stratification, and optimal combination strategies. By integrating mechanistic discovery with biomarker development and inhibitor optimization, this review aims to lay a foundation for the future development of PSMD14-targeted therapeutic strategies."

Journal • Review • Cardiovascular • Hepatocellular Cancer • Lung Cancer • Oncology • Pancreatic Cancer • Rheumatology • Solid Tumor • Targeted Protein Degradation • E2F1 • ER • IMPDH2 • PSMD14

Traditional Chinese medicine modulates tumor-associated macrophages to suppress gastric cancer progression: mechanisms and therapeutic potential. (PubMed, Front Oncol) - "Mechanistically, TAMs promote GC cell proliferation, invasion, and metastasis through the FOXQ1/EMT axis and exosomal ApoE/PI3K/AKT signaling pathways; promote angiogenesis through the VEGF/NF-κB and COX-2/MMP9 signaling pathways; induce resistance to 5-fluorouracil, cisplatin, and oxaliplatin via exosomal miR-21/PTEN, miR-1911-5p, and circ0008253; and mediate immune evasion through the PD-L1- and CLEVER-1-mediated immune checkpoint pathways. Active monomers, including Actinidia eriantha polysaccharide, Dendrobium officinale polysaccharide, sophoridine, and epigallocatechin gallate, promote M1-like macrophage polarization and reverse M2-like macrophage-mediated immunosuppression through the PD-1/PD-L1, STAT6/PPAR-γ/JAGGED1/NOTCH1, and TLR4/IRF3 signaling pathways. TCM-mediated TAM reprogramming represents a promising adjunctive strategy to enhance chemotherapy and immunotherapy efficacy in GC."

Journal • Review • Gastric Cancer • Oncology • Solid Tumor • APOE • MIR21 • MMP9 • NOTCH1 • PD-1 • PD-L1 • STAT6 • TLR4

Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial. (PubMed, J Clin Oncol) - "Capecitabine or XELOX did not significantly improve the 2-year OS rate over PF in DCRT for inoperable locally advanced ESCC. Capecitabine showed a lower incidence of grade ≥3 AEs than PF did."

Journal • Metastases • P3 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). (ASCO-GI 2023) - P3 | " Adults with previously untreated, unresectable locally advanced or metastatic GC/GEJC, regardless of PD-L1 expression, were randomized (1:1) to receive TIS (200 mg IV Q3W) plus ICC (oxaliplatin [130 mg/m² IV Q3W] and oral capecitabine [1,000 mg/m² BID, Days 1-14 Q3W] or cisplatin [80 mg/m² IV Q3W] and 5-fluorouracil [800 mg/m²/day IV, Days 1-5 Q3W]) or P+ICC. In RATIONALE 305, TIS+ICC provided significant and clinically meaningful improvement in OS vs P+ICC with well acceptable safety as 1L in PD-L1+ patients with advanced GC/GEJC. These data suggest this combination is a new 1L option for this patient population. Clinical trial information: NCT03777657."

Clinical • IO biomarker • Metastases • P3 data • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor • HER-2 • PD-L1

Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial. (PubMed, J Clin Oncol) - "Two hundred and sixty-three patients with International Germ Cell Cancer Consensus Group poor prognosis received one cycle of bleomycin, etoposide, and cisplatin (BEP): 51 with a favorable tumor marker decline continued with three cycles of BEP (Fav-BEP) and 203 with an unfavorable decline were randomly treated with three BEP (Unfav-BEP) cycles or a dose-dense regimen (Unfav-dose-dense; two cycles of paclitaxel-BEP-oxaliplatin + two cycles of cisplatin, ifosfamide, and bleomycin). Salvage high-dose chemotherapy plus a stem-cell transplant was used in 8% in the Unfav-dose-dense arm and 17% in the Unfav-BEP arm (P = .035). Long-term outcomes suggest a sustained benefit of intensified chemotherapy in terms of PFS and numerically better survival, with a minimal toxicity and reduced use of salvage high-dose chemotherapy plus stem-cell transplant."

Journal • P3 data • Bone Marrow Transplantation • Germ Cell Tumors • Oncology • Transplantation

Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The phase III KEYNOTE-585 study (ESMO 2023) - P3 | "Methods Patients (pts) with untreated, locally-advanced, resectable G/GEJ cancer were randomized 1:1 to neoadjuvant pembro 200 mg IV Q3W or pbo + chemo (cisplatin + capecitabine or cisplatin + 5-FU) for 3 cycles...In the FLOT cohort, pts were randomized 1:1 to pembro + docetaxel, oxaliplatin, leucovorin, and 5-FU, Q2W...Outcomes in the main + FLOT cohort are in the Table. Table: LBA74 Outcomes in main + FLOT cohort Efficacy Pembro + chemoN = 502 Pbo + chemoN = 505 Treatment difference (95% CI) Path CRa, % 13.0 (10.2-16.3) 2.4 (1.3-4.2) 10.6% (7.4-14.0) P<0.0001 Median EFS, mo (95% CI) 45.8 (35.9-NR) 25.7 (21.9-33.9) HR 0.81 (0.68-0.97) P=0.011 Median OS, mo (95% CI) 60.7 (51.5-NR) NR (45.7-NR) HR 0.93 (0.76-1.12) Safety Pembro + chemoN = 498 Pbo + chemoN = 503 NA Grade ≥ 3 drug-related AEs 67% 63% NA aIn first 987 pts randomized; HR, hazard ratio; NA, not applicable; NR, not reached Conclusions Neoadjuvant/adjuvant pembro + chemo followed by adjuvant pembro,..."

Clinical • Late-breaking abstract • Metastases • P3 data • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Neo-AEGIS (Neoadjuvant Trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Final primary outcome analysis. (ASCO-GI 2023) - P3 | "Neo-AEGIS was designed as the first randomized clinical trial (RCT) to directly compare the multimodal CROSS regimen (carboplatin/paclitaxel, 41.4Gy radiation therapy) with a modified MAGIC (epirubicin, cisplatin (oxaliplatin), 5-FU (capecitabine)) regimen (pre-2018) and more latterly the FLOT (docetaxel, 5-FU, leucovorin, oxaliplatin) regimen... This RCT reveals no evidence that peri-operative chemotherapy is unacceptably inferior to multimodal therapy in the primary outcome of overall survival, notwithstanding greater proxy markers of local tumor response in the CROSS arm. Oncologic and operative outcomes were consistent with optimum modern benchmarks. These data strongly suggest non-inferiority and support equipoise in clinical decision making in modern practice."

Clinical • Esophageal Adenocarcinoma • Esophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology

Final analysis of the phase III KEYNOTE-585 study of pembrolizumab plus chemotherapy vs chemotherapy as perioperative therapy in locally-advanced gastric and gastroesophageal junction cancer (ESMO-GI 2024) - P3 | "Methods Eligible pts with untreated, locally advanced, resectable G/GEJ cancer were randomized 1:1 to neoadjuvant pembro 200 mg IV Q3W or pbo + chemo (cisplatin + capecitabine or cisplatin + 5-FU) for 3 cycles...In the FLOT cohort, pts were randomized 1:1 to pembro or pbo + docetaxel, oxaliplatin, leucovorin, and 5-FU, Q2W...Outcomes in the main + FLOT cohort are in the table. Conclusions Efficacy and safety outcomes with neoadjuvant/adjuvant pembro + chemo followed by adjuvant pembro in pts with untreated, locally advanced resectable G/GEJ cancer at final analysis, were consistent with the prior analysis."

Late-breaking abstract • Metastases • P3 data • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor

Phase II study of neoadjuvant chemotherapy with fluorouracil, leucovorin, oxaliplatin and docetaxel for resectable esophageal squamous cell carcinoma: Survival analysis. (ASCO-GI 2026) - "Background: Based on the JCOG1109 trial, the combination of neoadjuvant docetaxel, cisplatin, and fluorouracil (DCF) followed by esophagectomy has become the standard of care for resectable locally advanced esophageal squamous cell carcinoma (ESCC). After follow up, neoadjuvant FLOT therapy demonstrated acceptable OS and PFS. This regimen may be considered as a treatment option for resectable locally advanced ESCC. Clinical trial information: jRCTs031200094."

Clinical • P2 data • Esophageal Adenocarcinoma • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastrointestinal Cancer • Oncology

Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in HER2-negative advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma (GC/GEJC): PD-L1 biomarker analysis from RATIONALE-305 (ESMO-GI 2024) - P3 | "Here we report exploratory analyses of OS subgroup results by PD-L1 expression status and concordance between PD-L1 TAP score and combined positive score (CPS). Adults with GC/GEJC were randomized (1:1) to IV TIS 200 mg or PBO every 3 weeks + investigator-chosen CT (oxaliplatin + capecitabine or cisplatin + 5-fluorouracil). The addition of TIS to CT as 1L treatment for GC/GEJC improved OS in pts with PD-L1 TAP ≥10% and ≥1%. These data, with prior data from pts with PD-L1 TAP ≥5% and all randomized pts, support TIS + CT as a new 1L treatment option for advanced HER2-negative GC/GEJC. Concordant TAP and CPS results suggest both methods are viable for clinical PD-L1 expression measurement in pts with GC/GEJC."

Biomarker • Clinical • IO biomarker • Metastases • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • HER-2 • PD-L1

Neoadjuvant and adjuvant pembrolizumab plus chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: Outcomes from the microsatellite instability-high population of the phase 3 KEYNOTE-585 study. (ASCO 2026) - P3 | "Pts enrolled in the main cohort (n = 804) received neoadjuvant pembro 200 mg intravenously (IV) every 3 weeks (Q3W) or pbo plus chemo (cisplatin + capecitabine or 5-FU) for 3 cycles; after surgery, pts received adjuvant pembro or pbo plus chemo Q3W for 3 cycles, then adjuvant pembro or pbo Q3W for 11 cycles. Pts in the fluorouracil, docetaxel, and oxaliplatin (FLOT) cohort (n = 203) received neoadjuvant pembro 200 mg IV Q3W or pbo Q3W for 3 cycles plus FLOT Q2W for 4 cycles; after surgery, pts received adjuvant pembro or pbo Q3W for 3 cycles plus FLOT Q2W for 4 cycles, then adjuvant pembro or pbo Q3W for 11 cycles... In this post hoc analysis, efficacy outcomes for pts with MSI-H G/GEJ adenocarcinoma suggested a consistent trend with numerically more pronounced difference between the treatment groups, with a manageable safety profile. Further studies in this population are warranted."

Clinical • Metastases • MSI-H • P3 data • Gastric Adenocarcinoma • Gastroesophageal Junction Adenocarcinoma • Microsatellite Instability • Oncology • Solid Tumor • MSI

Preoperative Chemoradiotherapy for Resectable Gastric Cancer. (PubMed, N Engl J Med) - P2/3 | "The addition of preoperative chemoradiotherapy to perioperative chemotherapy did not improve overall survival as compared with perioperative chemotherapy alone among patients with resectable gastric and gastroesophageal junction adenocarcinoma. (Funded by the National Health and Medical Research Council and others; TOPGEAR ClinicalTrials.gov number, NCT01924819.)."

Journal • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor

Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma. (PubMed, ESMO Open) - "These findings suggest a potential association between pCR, mPR, or pDS and survival in patients with locally advanced gastric or GEJ adenocarcinoma, although further validation is needed."

Journal • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor